Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faropenem and Cefadroxil in Pulmonary Tuberculosis
NCT02381470Phase 2Completed
- Sponsor
- National University Hospital
- Start
- Feb 2019
- Primary completion
- Sep 2019
- Modality
- Reversible Covalent Inhibitors
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of faropenem and cefadroxil in pulmonary tuberculosis (TB) (3 arms), sponsored by National University Hospital. Primary endpoint: Rate of change of time to positivity (TTP) in liquid culture. Started Feb 2019; status: completed.
02
Drugs
faropenemcefadroxil
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT02381470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02381470.